Protara Therapeutics reported a net loss of $0.37 per share for the fourth quarter of 2025, a modest improvement over the $0.48 loss posted in the same period a year earlier. For the full year, the company’s loss narrowed to $1.34 per share from $1.78 a year ago, reflecting tighter cost control and a more efficient allocation of research and development resources.
Cash, cash equivalents and investments totaled $198 million as of December 31 2025, giving Protara a runway that extends into 2028. The strong liquidity position provides a cushion for continued investment in late‑stage clinical trials and positions the company to weather the high‑cost, long‑duration development cycle typical of a clinical‑stage biopharma.
R&D and general‑administrative expenses rose in 2025 as the company accelerated its two‑platform pipeline. The increase was driven by expanded clinical activity for TARA‑002 in non‑muscle invasive bladder cancer and for IV Choline Chloride in patients on long‑term parenteral support, as well as by the costs associated with regulatory submissions and the management of multiple late‑stage studies.
Protara’s pipeline remains a key focus. TARA‑002, a therapeutic derived from the same master cell bank as OK‑432, has received Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations for bladder cancer and lymphatic malformations. Interim Phase 2 data show complete response rates above 65% in both BCG‑unresponsive and BCG‑naïve cohorts, and the company remains on track to complete enrollment. IV Choline Chloride has earned Orphan Drug and Fast Track designations for patients dependent on parenteral nutrition, and the seamless Phase 2b/3 THRIVE‑3 trial is underway.
Analysts had estimated a fourth‑quarter EPS of ($0.34) to ($0.35). Protara’s reported loss of ($0.37) per share missed expectations by $0.02 to $0.03, a modest shortfall that reflects the company’s continued investment in clinical development. The miss underscores the high‑cost nature of the company’s current pipeline stage, even as the cash runway remains robust.
CEO Jesse Shefferman emphasized the company’s progress: "Over the last few months, we reported meaningful clinical and regulatory progress across our portfolio of late‑stage programs and are building on this momentum as we advance toward several important milestones in 2026." He added, "For TARA‑002 in non‑muscle invasive bladder cancer (NMIBC), the clinical dataset continues to support its potential as a differentiated intravesical therapy with compelling efficacy, a favorable safety profile and a streamlined approach to administration in the clinical setting for both BCG‑Unresponsive and BCG‑Naïve patients. We remain on track to complete enrollment in…" Shefferman also noted, "We believe that IV Choline Chloride has the potential to make a meaningful impact in this highly underserved population and could ultimately become the first FDA‑approved IV choline therapy for patients dependent on PS."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.